Oculopharyngeal muscular dystrophy: Recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1772, Issue 2, 2007, Pages 173-185

  Abu Baker, Aida ^a   Rouleau, Guy A ^a  

^a NOTRE DAME HOSPITAL   (Canada)

Author keywords

Intranuclear inclusions; Oculopharyngeal muscular dystrophy; Poly(A) binding protein nuclear 1; Polyalanine

Indexed keywords

8 QUINOLINOL; ALANINE; DOXYCYCLINE; IBUPROFEN; INDOMETACIN; MESSENGER RNA; MESSENGER RNA PRECURSOR; NUCLEAR PROTEIN; POLYADENYLIC ACID BINDING PROTEIN; POLYAMINOACID; POLYGLUTAMINE; PROTEIN ANTIBODY; PROTEIN PABPN1; SINGLE DOMAIN INTRACELLULAR ANTIBODY; TREHALOSE; UNCLASSIFIED DRUG; ZINC SULFATE;

CELL NUCLEUS INCLUSION BODY; CELL THERAPY; CLINICAL FEATURE; DYSPHAGIA; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; LIMB WEAKNESS; NONHUMAN; NUCLEOCYTOPLASMIC TRANSPORT; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; ONSET AGE; PABPN1 GENE; POLYADENYLATION; PRIORITY JOURNAL; PTOSIS; REVIEW; SKELETAL MUSCLE; TRANSCRIPTION REGULATION; TRINUCLEOTIDE REPEAT;

ANIMALS; HUMANS; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL;

EID: 33846440511     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2006.10.003     Document Type: Review

References (129)

1. Fried K., Arlozorov A., and Spira R. Autosomal recessive oculopharyngeal muscular dystrophy. J. Med. Genet. 12 (1975) 416-418
2. Duranceau A.C., Beauchamp G., Jamieson G.G., and Barbeau A. Oropharyngeal dysphagia and oculopharyngeal muscular dystrophy. Surg. Clin. North Am. 63 (1983) 825-832
3. Brais B., Rouleau G.A., Bouchard J.P., Fardeau M., and Tome F.M. Oculopharyngeal muscular dystrophy. Semin. Neurol. 19 (1999) 59-66
4. Taylor E.W. Progressive vagus-glossopharyngeal paralysis with ptosis: a contribution to the group family diseases. J. Nerv. Ment. Dis. 42 (1915) 129-139
5. Victor M., Hayes R., and Adams R.D. Oculopharyngeal muscular dystrophy: familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N. Engl. J. Med. 267 (1962) 1267-1272
6. Vita G., Dattola R., Santoro M., and Messina C. Familial oculopharyngeal muscular dystrophy with distal spread. J. Neurol. (1983) 57-64
7. Lim C.T., Chew C.T., and Chew S.H. Oculopharyngeal muscular dystrophy: a case report and a review of literature. Ann. Acad. Med. Singap. 21 (1992) 399-403
8. Blumen S.C., Nisipeanu P., Sadeh M., Asherov A., Tome F.M., and Korczyn A.D. Clinical features of oculopharyngeal muscular dystrophy among Bukhara Jews. Neuromuscul. Disord. 3 (1993) 575-577
9. Jongen P.J., Ter Laak H.L., and Stadhouders A.M. Rimmed basophilic vacuoles and filamentous inclusions in neuromuscular disorders. Neuromuscul. Disord. 5 (1995) 31-38
10. Uyama E., Nohira O., Chateau D., Tokunaga M., Uchino M., Okabe T., Ando M., and Tome F.M. Oculopharyngeal muscular dystrophy in two unrelated Japanese families. Neurology 46 (1996) 773-778
11. The B.T., Sullivan A.A., Farnebo F., Zander C., Li F.Y., Strachan N., Schalling M., Larsson C., and Sandstrom P. Oculopharyngeal muscular dystrophy (OPMD)-Report and genetic studies of an Australian Kindred. Clin. Genet. 51 (1997) 52-55
12. Fardeau M., and Tome F.M. Oculopharyngeal muscular dystrophy in France. Neuromuscul. Disord. 7 Suppl. 1 (1997) S30-S33
13. Blumen S.C., Nisipeau P., Sadeh M., Asherov A., Blumen N., Wirguin Y., Khilkevich O., Carasso R.L., and Korczyn A.D. Epidemiology and inheritance of oculopharyngeal muscular dystrophy in Israel. Neuromuscul. Disord. vol. 7 (1997) S38-S40 (Suppl. 1)
14. Medici M., Pizzarossa C., Skuk D., Yorio D., Emmanuelli G., and Mesa R. Oculopharyngeal muscular dystrophy in Urguay. Neuromuscul. Disord. 7 Suppl. 1 (1997) S50-S52
15. Meola G., Sansone V., Rotondo G., Tome F.M., and Bouchard J.P. Oculopharyngeal muscular dystrophy in Italy. Neuromuscul. Disord. 7 Suppl. 1 (1997) S53-S56
16. Porschke H., Kress W., Reichmann H., Goebel H.H., and Grimm T. Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency. Neuromuscul. Disord. 7 Suppl. 1 (1997) S57-S62
17. Brais B., Xie Y.G., Sanson M., Morgan K., Weissenbach J., Korczyn A.D., Blumen S.C., Fardeau M., Tome F.M., Bouchard J.P., and Rouleau G.A. The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum. Mol. Genet. 4 (1995) 429-434
18. Brunet G., Tome F.M., Samson F., et al. Dytrophie musculaire oculopharyngee. Recensement des familles francaises et etude genealogique. Rev. Neurol. 4 (1990) 429-434
19. Barbeau A. In: Kuhn E. (Ed). Symposium Uber Progressive Muskeldystrophie (1966), Springer-Verlag, Berlin 102-109
20. Tomé F., and Fardeau M. In: Engel A.G., and Franzini-Armstrong C. (Eds). Oculopharyngeal muscular dystrophy. Myology vol. 2 (1994), McGraw-Hill, New York 1233-1245
21. Fan X., and Rouleau G.A. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci. 30 (2003) 8-14
22. Tome F.M., and Fardeau M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol. (Berl.) 49 (1980) 85-87
23. Rüegg S., Lehky Hagen M., Hohl U., Kappos L., Fuhr P., Plasilov M., Hüller H., and Heinimann K. Oculopharyngeal muscular dystrophy an under-diagnosed disorder?. Swiss Med. Wkly. 135 (2005) 574-586
24. Brais B. Oculopharyngeal muscular dystrophy: a late-onset polyalanine disease. Cytogenet. Genome Res. 100 (2003) 252-260
25. Bouchard J.P., Brais B., Brunet D., Gould P.V., and Rouleau G.A. Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul. Disord. 7 Suppl 1 (1997) S22-S29
26. Little B.W., and Perl D.P. Oculopharyngeal muscular dystrophy. An autopsied case from the French-Canadian Kindred. J. Neurol. Sci. 53 (1982) 145-158
27. van der Sluijs B.M., Hoefsloot L.H., Padberg G.W., van der Maarel S.M., and van Engelen B.G.M. Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. J. Neurol. 250 (2003) 1307-1312
28. Codere F. Oculopharyngeal muscular dystrophy. Can. J. Ophthalmol. 28 (1993) 1-2
29. Duranceau A. Cricopharyngeal myotomy in the management of neurogenic and muscular dysphagia. Neuromuscul. Disord. 7 (1997) S85-S89
30. Mathieu J., Lapointe G., Brassard A., Tremblay C., Brais B., Rouleau G.A., and Bouchard J.P. A pilot study on upper esophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul. Disord. 7 (1997) S100-S104
31. Stajich J.M., Gilchrist J.M., Lennon F., Lee A., Yamaoka L., Rosi B., Gaskell P.C., Pritchard M., Donals L., Roses A.D., Vance J.M., and Pericak-Vance M.A. Confirmation of linkage of oculopharyngeal muscular dystrophy to chromosome 14q11.2-q13 in American families suggests the existence of a second causal mutation. Neuromuscul. Disord. 1 (1997) S75-S81
32. Porschke H., Kress W., Reichmann H., Goebel H.H., and Grimm T. Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency. Neuromuscul. Disord. 7 Suppl 1 (1997) S57-S62
33. Brais B., Bouchard J.P., Xie Y.G., Rochefort D.L., Chrétien N., Tomé F.M., Lafreniere R.G., Rommens J.M., Uyama E., Nohira O., Blumen S., Korczyn A.D., Heutink P., Mathieu J., Duranceau A., Codere F., Fardeau M., and Rouleau G.A. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 18 (1998) 164-167
34. Blumen S.C., Brais B., Korczyn A.D., Medinsky S., Chapman J., Asherov A., et al. Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann. Neurol. 46 (1999) 115-118
35. Pobst A., Tackmann W., Stoeckli H.R., Jerusalem F., and Ulrich J. Evidence for a chronic axonal atrophy in oculopharyngeal 'muscular dystrophy'. Acta Neuropathol. (Berl.) 57 (1982) 209-216
36. Schober R., Kress W., Grahmann F., Kellermann S., Baum P., Gunzel S., and Wagner A. Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology 21 (2001) 45-52
37. Bouchard P., Brais B., Brunet D., Gould P.V., and Rouleau G.A. Recent studies on oculopharyngeal muscular dystrophy in Québec. Neuromuscul. Disord. 7 Suppl. 1 (1997) S22-S29
38. Schmitt P., and Krause K.H. An autopsy study of a familial oculopharyngeal muscular dystrophy (OPMD) with dustal spread and neurogenic involvement. Muscle Nerve 4 (1981) 296-305
39. Hardiman O., Halperin J.J., Farell M.A., Shapiro B.E., Wray S.H., and Brown R.H. Neuropathic findings in oculopharyngeal muscular dystrophy. A report of seven cases and a review of the literature. Arch. Neurol. 50 (1993) 481-488
40. Mirabella M., Silvestri G., de Rosa G., Di Giovanni S., Di Muzio A., Uncini A., Tonali P., and Servidei S. GCG genetic expansions in Italian patients with oculopharyngeal muscular dystrophy. Neurology 54 (2000) 608-614
41. Müller T., Schröder R., and Zierz S. GCG repeats and phenotype in oculopharyngeal muscular dystrophy. Muscle Nerve 24 (2001) 120-122
42. Schober R., Kress W., Grahmann F., Kellermann S., Baum P., Günzel S., and Wagner A. Unusual triplet expansion associated with neurogenic changes in a family with oculopharyngeal muscular dystrophy. Neuropathology 21 (2001) 45-52
43. Boukriche Y., Maisonobe T., and Masson C. Neurogenic involvement in a case of oculopharyngeal muscular dystrophy. Muscle Nerve 25 (2002) 98-101
44. Linoli G., Tomelleri G., and Ghezzi M. Oculopharyngeal muscular dystrophy. Description of a case with involvement of the central nervous system. Pathologica 83 (1991) 325-334
45. Boukriche Y., Maisonobe T., and Masson C. Neurogenic involvement in a case of oculopharyngeal muscular dystrophy. Muscle Nerve 25 (2002) 98-101
46. Nakashima D., Nakajima H., Ishida S., Sugino M., Kimura F., and Hanafusa T. Preferential distal muscle involvement in case of oculopharyngeal muscular dystrophy with (GCG) 13 expansion. Rinsho Shinkeigaku 43 (2003) 560-563
47. Dion P., Shanmugam V., Gaspar C., Messaed C., Meijer I., Toulouse A., Laganiere A.J., Roussel J., Rochefort D., Laganiere S., Allen A., Karpati G., Bouchard J.P., Brais B., and Rouleau G.A. Transgenic expression of an expanded (GCG)13 repeat PABPN1 leads to weakness and coordination defects in mice. Neurobiol Dis. 3 (2005) 528-536
48. Tomé F.M.S., Chateau D., Helbling-Leclerc A., and Fardeau M. Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul. Disord. 7 Suppl 1 (1997) S63-S69
49. Krause S., Fakan S., Weis K., and Wahle E. Immunodetection of poly(A) binding protein II in the cell nucleus. Exp. Cell Res. 214 (1994) 75-82
50. Wahle E., Lustig A., Jeno P., and Maurer P. Mammalian poly(A)-binding protein II. Physical properties and binding to polynucleotides. J. Biol. Chem. 268 (1993) 2937-2945
51. Nemeth A., Krause S., Blank D., Jenny A., Jeno P., Lusting A., and Wahle E. Isolation of genomic and cDNA clones encoding bovine poly(A) binding protein II. Nucleic Acids Res. 23 (1995) 4034-4041
52. Kerwitz Y., Kühn U., Lilie H., Knoth A., Scheuermann T., Friedrich H., Schwarz E., and Wahle E. Stimulation of poly(A) polymerase through a direct interaction with the nuclear poly(A) binding protein allosterically regulated by RNA. EMBO J. 22 (2003) 3705-3714
53. Calado U., Kutay U., Kühn E., Wahle E., and Carmo-Fonseca M. Deciphering the cellular pathway for transport of poly(A)-binding protein II. RNA 6 (2000) 245-256
54. Fan X., Dion P., Laganiere J., Brais B., and Rouleau G.A. Oligomerization of polyalanine expanded PABPN1 facilitates nuclear protein aggregation that is associated with cell death. Hum. Mol. Genet. 10 (2001) 2341-2351
55. Wahle E. A novel poly(A)-binding protein acts as a specificity factor in the second phase of messenger RNA polyadenylation. Cell 66 (1991) 759-768
56. Wahle E. Poly(A) tail length control is caused by termination of processive synthesis. J. Biol. Chem. 270 (1995) 2800-2808
57. Gorlach M., Burd C.G., and Dreyfuss G. The mRNA poly(A)-binding protein: localization, abundance, and RNA-binding specificity. Exp. Cell Res. 211 (1994) 400-407
58. Afonina E., Stauber R., and Pavlakis G.N. The human poly(A)-binding protein 1 shuttles between the nucleus and the cytoplasm. J. Biol. Chem. 273 (1998) 13015-13021
59. Calado A., Tome F.M.S., Brais B., Rouleau GA., Kuhn U., Wahle E., and Carmo-Fonseca M. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly (A) binding protein 2 aggregates which sequester poly(A) RNA. Hum. Mol. Genet. 9 (2000) 2321-2328
60. Colgan D.F., and Manley J.L. Mechanism and regulation of mRNA polyadenylation. Genes Dev. 11 (1997) 2755-2766
61. Minvielle-Sebastia L., and Keller W. mRNA polyadenylation and its coupling to other RNA processing reactions and to transcription. Curr. Opin. Cell Biol. 11 (1999) 352-357
62. Barabino S.M.L., and Keller W. Last but not least: regulated poly(A) tail formation. Cell 99 (1999) 9-11
63. Bienroth S., Keller W., and Wahle E. Assembly of a processive messenger RNA polyadenylation complex. EMBO J. 12 (1993) 585-594
64. Keller R.W., Kuhn U., Aragon M., Bornikova L., Wahle E., and Bear D.G. The nuclear poly(A) binding protein, PABP2, forms an oligomeric particle covering the length of the poly(A) tail. J. Mol. Biol. 297 (2000) 569-583
65. Tome F.M., and Fardeau M. Ocular myopathies. Pathol. Res. Pract. 180 (1985) 19-27
66. Pratt F., and Meyers P.K. Oculopharyngeal muscular dystrophy: recent ultrastructural evidence for mitochondrial abnormalities. Laryngoscope 96 (1986) 368-373
67. Tome F.M., Askanas V., Engel W.K., Alvarez R.B., and Lee C.S. Nuclear inclusions in innervated cultured muscle fibers from patients with oculopharyngeal muscular dystrophy. Neurology 39 (1989) 929-932
68. Bouchard J.P., Gagne F., Tome F.M., and Brunet D. Nuclear inclusions in oculopharyngeal muscular dystrophy in Quebec. Can. J. Neurol. Sci. 16 (1989) 446-450
69. Coquet M., Vital C., and Julien J. Presence of inclusion body myositis-like filaments in oculopharyngeal muscular dystrophy. Ultrastructural study of 10 cases. Neuropathol. Appl. Neurobiol. 5 (1990) 393-400
70. Blumen S.C., Sadeh M., Korczyn A.D., Rouche A., Nisipeanu P., Asherov A., and Tome F.M. Intranuclear inclusions in oculopharyngeal muscular dystrophy among Bukhara Jews. Neurology 46 (1996) 1324-1328
71. Tome F.M.S., and Fradeau M. Nuclear changes in muscle disorders. Methods Achiev. Exp. Pathol. 12 (1986) 261-296
72. Bao Y.P., Cook L.J., O'Donovan D., Uyama E., and Rubinsztein D.C. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem. 277 (2002) 12263-12269
73. Abu-Baker A., Messaed C., Laganiere J., Gaspar C., Brais B., and Rouleau G.A. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 12 (2003) 2609-2623
74. Shanmugam V., Dion P., Rochefort D., Laganiere J., Brais B., and Rouleau G.A. PABP2 polyalanine tract expansion causes intranuclear inclusions in oculopharyngeal muscular dystrophy. Ann. Neurol. 48 (2000) 798-802
75. Abu-Baker A., Laganiere S., Fan X., Laganiere J., Brais B., and Rouleau G.A. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy. Traffic 6 (2005) 1-14
76. Corbeil-Girard L.P., Klein A.F., Sasseville A.M., Lavoie H., Dicaire M.J., Saint-Denis A., Page M., Duranceau A., Codere F., Bouchard J.P., Karpati G., Rouleau G.A., Massie B., Langelier Y., and Brais B. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol. Dis. 18 (2005) 551-567
77. Arrasate M., Mitra S., Schweitzer E.S., Segal M.R., and Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 43 (2004) 805-810
78. Tavanez J.P., Calado P., Braga J., Lafarga M., and Carmo-Fonseca M. In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA 5 (2005) 752-762
79. Berciano T.M., Nuria T., Jose V., Navascues L.O.J., Gomes A., and Lafarga M. Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus. Hum. Mol. Genet. 13 (2004) 829-838
80. Sasseville A.M.J., Caron A.W., Bourget L., Klein A.F., Dicaire M.J., Rouleau G.A., Massie B., Langelier Y., and Brais B. The dynamism of PABPN1 nuclear inclusions during the cell cycle. Neurobiol. Dis. 23 (2006) 621-629
81. Abu-Baker A., and Rouleau G.A. Polyalanine and Polyglutamine Diseases: possible Common Mechanisms?. Genetic Instabilities and Neurological disorders. 2nd ed. (2006) 487-513 (Chapter 33)
82. Zoghbi H.Y., and Orr H.T. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23 (2000) 217-247
83. Gaspar C., Jannatipour M., Dion P., Laganiere J., Sequeiros J., Brais B., and Rouleau G.A. CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation. Hum. Mol. Genet. 9 (2000) 1957-1966
84. Toulouse A., Au-Yeung F., Gaspar C., Roussel J., Dion P., and Rouleau G.A. Ribosomal frameshifting on MJD-1 transcripts with long CAG tracts. Hum. Mol. Genet. 15 (2005) 2649-2660
85. Muragaki Y., Mundlos S., Upton J., and Olsen B.R. Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13. Science 272 (1996) 548-551
86. Goodman F.R., Mundlos S., Muragaki Y., Donnai D., Giovannucci-Uzielli M.L., Lapi E., Majewski F., McGaughran J., McKeown C., Reardon W., Upton J., Winter R.M., Olsen B.R., and Scambler P.J. Synpolydactyly phenotypes correlate with size of expansions in HOXD13 polyalanine tract. Proc. Natl. Acad. Sci. 94 (1997) 7458-7463
87. Mundlos S., Otto F., Mundlos C., Mulliken J.B., Aylsworth A.S., Albright S., Lindhout D., Cole W.G., Henn W., Knoll J.H., Owen M.J., Mertelsmann R., Zabel B.U., and Olsen B.R. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell 89 (1997) 773-779
88. Brown S.A., Warburton D., Brown L.Y., Yu C.-Y., Roeder E.R., Stengel-Rutkowski S., Hennekam R.C.M., and Muenke M. Holoprosencephaly due to mutation in ZIC2 a homologue of Drosophila odd-paired. Nat. Genet. 20 (1998) 180-183
89. Mortlock D.P., and Innis J.W. Mutation of HOXA13 in hand-foot-genital syndrome. Nat. Genet. 15 (1997) 179-180
90. Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P., Bisceglia L., Zelante L., Nagaraja R., Porcu S., Ristaldi S.M.S., R.Marzella M., Rocchi M., Nicolino A., Lienhardt-Roussie A., Nivelon A., Verloes D., Schlessinger P., Gasparini D., Bonneau A., and Cao G. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet. 27 (2001) 159-166
91. Stromme P., Mangelsdorf M.E., Shaw M.A., Lower K.M., Lewis S.M., Bruyere H., Lutcherath V., Gedeon A.K., Wallace R.H., Scheffer I.E., Turner G., Partington M., Frints S.G., Fryns J.P., Sutherland G.R., Mulley J.C., and Gecz J. Mutations in the human ortholog of Aristaless cause X-linked mental retardation and epilepsy. Nat. Genet. 30 (2002) 441-445
92. Laumonnier F., Ronce N., Hamel B.C., Thomas P., Lespinasse J., Raynaud M., Paringaux C., Van Bokhoven H., Kalscheuer V., Fryns J.P., Chelly J., Moraine C., and Briault S. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am. J. Hum. Genet. 71 (2002) 1450-1455
93. Amiel J., Laudier B., Attie-Bitach T., Trang H., De Pontual L., Gener B., Trochet D., Etchevers H., Ray P., Simonneau M., Vekemans M.M., Munnich A., Gaultier G., and Lyonnet S. Polyalanine expansion and frameshift mutations of the paired-like homeobox gene PHOX2B in congenital central hypoventilation syndrome. Nat. Genet. 33 (2003) 459-461
94. Warren S.T. Polyalanine expansion in synpolydactyly might result from unequal crossing-over of HOXD13. Science 275 (1997) 408-409
95. Lavoie H., Debeane F., Trinh Q.D., Turcotte J.F., Corbeil-Girard L.P., Dicaire M.J., Saint-Denis A., Page M., Rouleau G.A., and Brais B. Polymorphism, shared functions and convergent evolution of genes with sequences coding for polyalanine domains. Hum. Mol. Genet. 12 (2003) 2967-2979
96. Caburet S., Demarez A., Moumme L., Fellows M., De Baere E., and Veitia R.A. A recurrent polyalanine expansion in the transcription factor FOXL2 induces extensive nuclear and cytoplasmic protein aggregation. J. Med. Genet. 41 (2004) 931-946
97. Nasrallah I.M., Minarcik J.C., and Golden J.A. A polyalanine tract expansion in Arx forms intranuclear inclusions and results in increased cell death. J. Cell Biol. 167 (2004) 411-416
98. Albrecht A.N., Kornak U., Boddrich A., Suring K., Robinson P.N., Stiege A.C., Lurz R., Stricker S., Wanker E.E., and Mundlos S. A molecular pathogenesis for transcription factor associated poly-alanine tract expansions. Hum. Mol. Genet. 13 (2004) 2351-2359
99. Goodman F.R. Limb malformations and the human HOX genes. Am. J. Med. Genet. 112 (2002) 256-265
100. Goodman F.R., and Scambler P.J. Human HOX gene mutations. Clin. Genet. 59 (2001) 1-11
101. Amiel J., Trochet D., Clement-Ziza M., Munnich A., and Lyonnet S. Polyalanine expansions in human. Hum. Mol. Genet. 13 (2004) R235-R243
102. Albrecht A., and Mundlos S. The other trinucleotide repeat: polyalanine expansion disorders. Curr. Opin. Genet. Dev. 3 (2005) 285-293
103. Davies J.E., Wang L., Garcia-Oroz L., Cook L.J., Vacher C., O'donovan D.G., and Rubinsztein D.C. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med. 6 (2005) 672-677
104. Hino H., Araki K., Uyama E., Takeya M., Araki M., Yoshinobu K., Miike K., Kawazoe Y., Maeda Y., Uchino M., and Yamamura K. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 13 (2004) 181-190
105. Chartier A., Benoit B., and Simonelig M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J. 25 (2006) 2253-2262
106. Fan X., Messaed C., Dion P., Laganiere L., Brais B., Karpati G., and Rouleau G.A. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci. 30 (2003) 244-251
107. Forood B., Perez-Paya E., Houghten R.A., and Blondelle S.E. Formation of an extremely stable polyalanine beta-sheet macromolecule. Biochem. Biophys. Res. Commun. 211 (1995) 7-13
108. Blondelle S.E., Forood B., Houghten R.A., and Perez-Paya E. Polyalanine-based peptides as models for self-associated beta-pleated-sheet complexes. Biochemistry 36 (1997) 8393-8400
109. Gatesy J., Hayashi C., Motriuk D., Woods J., and Lewis R. Extreme diversity, conservation, and convergence of spider silk fibroin sequences. Science 291 (2001) 2603-2605
110. Karlin S., Chen C., Gentles A.J., and Cleary M. Associations between human disease genes and overlapping gene groups and multiple amino acid runs. Proc. Natl Acad. Sci. 99 (2002) 17008-17013
111. Perutz M.F., Pope B.J., Owen D., Wanker E.E., and Scherzinger E. Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl. Acad. Sci. 99 (2002) 5596-5600
112. Scheuermann T., Schulz B., Blume A., Wahle E., Rudolph R., and Schwarz E. Trinucleotide expansions leading to an extended poly-l-alanine segment in the poly (A) binding protein PABPN1 cause fibril formation. Protein Sci. 12 (2003) 2685-2692
113. Shinchuk L.M., Sharma D., Blondelle S.E., Reixach N., Inouye H., and Kirschner D.A. Poly-(l-alanine) expansions form core beta-sheets that nucleate amyloid assembly. Proteins 61 (2005) 579-589
114. Nguyen H.D., and Hall C.K. Spontaneous fibril formation by polyalanines; discontinuous molecular dynamics simulations. J. Am. Chem. Soc. 128 (2006) 1890-1901
115. Nguyen H.D., and Hall C.K. Kinetics of fibril formation by polyalanine peptides. J. Biol. Chem. 280 (2005) 9074-9082
116. Bao Y.P., Sarkar S., Uyama E., and Rubinsztein D.C. Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. J. Med. Genet. 41 (2004) 47-51
117. Sanchez I., Mahlke C., and Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 421 (2003) 373-379
118. Wirtschafter J.D., Ferrington D.A., and McLoon L.K. Continuous remodeling of adult extraocular muscles as an explanation for selective craniofacial vulnerability in oculopharyngeal muscular dystrophy. J. Neuroophthalmol. 1 (2004) 62-67
119. Wang Q., and Bag J. Ectopic expression of a polyalanine expansion mutant of poly(A)-binding protein N1 in muscle cells in culture inhibits myogenesis. Biochem. Biophys. Res. Commun. 340 (2006) 815-822
120. Kim Y.-J., Noguchi S., Hayashi Y.K., Tsukahara T., Shimizu T., and Arahata K. The product of an oculopharyngeal muscular dystrophy gene, poly(A)-binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum. Mol. Genet. 10 (2001) 1129-1139
121. Bear D.G., Fomproix N., Soop T., Björkroth B., Masich S., and Daneholt B. Nuclear poly(A)-binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore. Exp. Cell Res. 286 (2003) 332-344
122. Ravikumar B., Duden R., and Rubinsztein D.C. Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum. Mol. Genet. 11 (2002) 1107-1117
123. Nakielny S., and Dreyfuss G. Nuclear export of proteins and RNAs. Curr. Opin. Cell Biol. 9 (1997) 420-429
124. Berger Z., Ttofi E.K., Michel C.H., Pasco M.Y., Tenant S., Rubinsztein D.C., and O'Kane C.J. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum. Mol. Genet. 14 (2005) 3003-3011 (Hum Mol Genet)
125. Tanaka M., Machida Y., Niu S., Ikeda T., Jana N.R., Doi H., Kurosawa M., Nekooki M., and Nukina N. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat. Med. 10 (2004) 148-154
126. Davies J.E., Sarkar S., and Rubinsztein D.C. Trehalose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 15 (2006) 23-31
127. Verheesen P., de Kluijver A., van Koningsbruggen S., de Brij M., de Harrd H.J., van Ommen G.J., and van der Maarel S.M. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum. Mol. Genet. 15 (2006) 105-111
128. Wang Q., Mosser D.D., and Bag J. Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum. Mol. Genet. 14 (2005) 3673-3684
129. Mouly V., Aamiri A., Perie S., Mamchaoui K., Barani A., Bigot A., Bouazza B., Francois V., Furling D., Jacquemin V., Negroni E., Riederer I., Vignaud A., St Guily J.L., and Butler-Browne G.S. Myoblast transfer therapy: is there any light at the end of the tunnel?. Acta Myol. 2 (2005) 128-133